If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
395.00
Ask:
405.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

NHS Supply Chain listing

7 Nov 2008 07:00

RNS Number : 6707H
Tristel PLC
07 November 2008
 



 

TRISTEL plc

AIM: TSTL

High-level disinfection products for surfaces recommended by the NHS

Tristel Plc, a leading provider of infection control products into the NHS and private health sector, announces that the innovative product Fuse for Surfaces has been included in the NHS Supply Chain Catalogue and will be made available to all NHS organisations. This follows widespread adoption of Fuse for Surfaces during the course of the past 12 months by individual NHS hospitals sourcing the product directly from Tristel.

Tristel's chlorine dioxide solutions have been used in NHS endoscopy departments since the withdrawal of baldheads in the late 1990's. Chlorine dioxide (sometimes confused with chlorine but distinctly different), a well documented, highly effective, safe biocide is a powerful oxidising agent and is rapidly effective against all micro-organisms, including Clostridium difficile spores

Tristel has packaged its chlorine dioxide technology into a unique, easy to use 'burstable sachet'. Fuse for Surfaces delivers high-level disinfection of floors, walls and general hard surfaces in hospitals. No counting, weighing or calculations are needed to make up a working solution at the right concentration - and no waiting for chlorine tablets to dissolve. 

Paul Swinney, CEO of Tristel, said:

"Tristel offers a range of products, delivered in a variety of convenient formats that meet the individual decontamination needs that arise in endoscopy; ear, nose and throat; ultrasound; reproductive health and dentistry. Others tackle the challenges of disinfecting hospital and laboratory surfaces. We are especially pleased to have secured a place in the NHS Supply Chain Catalogue with our surfaces range of products".

Contacts:

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive

Daniel Stewart & Company Plc

Tel: 020 7776 6550

Graham Webster

Parkgreen Communications Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

About Tristel

Tristel uses proprietary chlorine dioxide chemistry to create instrument and surface disinfectants. With its origins as a healthcare business specialising in infection control products, Tristel has recently extended its operations to include legionella control in water supplies and contamination control in the food and pharmaceutical industries. 

The company is creating applications for its chemistry that address the four routes of transmission of infection and contamination - surfaces, instruments, water and people.

Tristel plc has its headquarters in NewmarketUK and a network of distributors around the world. The company was admitted to trading on AIM on 1 June 2005. Its stock exchange symbol is TSTL.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDQLFBVFBEFBB
Date   Source Headline
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
31st Mar 20258:56 amRNSHolding(s) in Company
26th Mar 202510:30 amRNSDirector/PDMR Shareholding
18th Mar 20252:39 pmRNSHolding(s) in Company
24th Feb 20257:00 amRNSUnaudited Interim Results
7th Feb 20257:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20257:00 amRNSDirector Option Grant
13th Jan 20257:00 amRNSConfirmation of Interim Results
16th Dec 20242:45 pmRNSResult of AGM
16th Dec 20247:00 amRNSAGM Statement and Notice of Interim Results
22nd Nov 202410:30 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Nov 20241:32 pmRNSExercise of Share Options and Total Voting Rights
20th Nov 20248:47 amRNSExercise of Share Options and Total Voting Rights
28th Oct 20241:37 pmRNSExercise of Share Options and Total Voting Rights
21st Oct 20247:00 amRNSFinal Results
1st Oct 20247:00 amRNSNotice of Preliminary Results
20th Sep 20247:00 amRNSDirector/PDMR Shareholding
19th Sep 20241:13 pmRNSExercise of Share Options and Total Voting Rights
12th Sep 20247:00 amRNSFDA 510(k) submission for Tristel OPH
2nd Sep 20247:00 amRNSConfirmation of CEO Transition, Directorate Change
6th Aug 20243:32 pmRNSExercise of Share Options and Total Voting Rights
22nd Jul 20247:00 amRNSTrading Update
4th Jul 20243:43 pmRNSExercise of Share Options and Total Voting Rights
11th Jun 20245:48 pmRNSDirector/PDMR Shareholding
11th Jun 20243:50 pmRNSHolding(s) in Company
10th Jun 20247:00 amRNSAppointment of CEO
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.